Johnson & Johnson additionally positive aspects an unique possibility to accumulate Sail Biosciences for $2.58 billion. The deal places J&J within the mixture of pharmaceutical firms growing next-generation cell therapies for purposes in autoimmune illnesses.
The submit J&J Joins Immune Reset Race, Paying $785M to Associate on Sail Bio Cell Remedy appeared first on MedCity Information.
